Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference

NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company specializing in the development of advanced treatments for various neurological conditions, has announced its participation in the upcoming 45th Annual TD Cowen Health Care Conference, scheduled for March 3-5, 2025.

Christopher U. Missling, PhD, who serves as the President and Chief Executive Officer of Anavex, will present during a designated session set for 9:50 AM (ET) on Monday, March 3, 2025. This event will take place at the Boston Marriott Copley Place, located in Boston, Massachusetts.

Anavex is keen to share insights about its ongoing research and advancements in treating complex conditions such as Alzheimer's disease, Parkinson's disease, schizophrenia, and other neurological and psychiatric disorders. The company has developed a robust pipeline of therapies, including its lead candidate, ANAVEX^®2-73 (blarcamesine), which is currently undergoing clinical trials.

For those unable to attend in person, a live audio webcast of the presentation will be available in the Investors section of the Anavex website at www.anavex.com. An archived version of the session will be posted later that same day for convenient access.

About Anavex Life Sciences Corp.

Based in New York, Anavex Life Sciences Corp. (Nasdaq: AVXL) is dedicated to developing novel therapeutics targeting neurodegenerative, neurodevelopmental, and neuropsychiatric disorders. Their innovative approach focuses on conditions such as Alzheimer's disease, Parkinson's disease, and Rett syndrome, among others. The company is notable for its lead drug ANAVEX^®2-73, which has demonstrated promising results in various clinical stages, showing potential to halt or reverse the progression of Alzheimer's disease and providing beneficial effects for other conditions.

ANAVEX^®2-73 works by re-establishing cellular balance through targeting specific receptors in the brain. It has also shown effectiveness in animal studies, which may lead to its use in treating additional neurological disorders, including epilepsy.

Future Perspectives and Risks

Looking ahead, Anavex aims to further explore the capabilities of its drug candidates, including ANAVEX^®3-71, which targets SIGMAR1 and M1 muscarinic receptors. This drug shows promise in modifying disease processes associated with Alzheimer's disease and mitigating its primary symptoms. However, like any biopharmaceutical endeavor, these advancements come with inherent risks and uncertainties.

It is essential for investors and stakeholders to understand that statements made about the company's future prospects involve predictions based on current knowledge and may not materialize as expected due to various factors. Anavex maintains its commitment to transparency and accountability regarding these forward-looking statements.

For those seeking additional information, Anavex encourages queries through their Research & Business Development team. Interested investors can also connect through various social media platforms, including Twitter, Facebook, and LinkedIn.

Anavex, Conference, Biopharmaceutical